Treatment
 
Day of study



9

16

23

30

37


Placebo

Range

17–26

20–28

15–26

21–27

19–26

Arithmetic mean (AM)

21.00

24.13

22.00

22.88

22.25

Geometric mean (GM)^{a}

20.79

23.98

21.69

22.80

22.15

Sarolaner

Range

0–0

0–2

0–2

0–3

0–1

Arithmetic mean (AM)

0

0.38

0.50

1.25

0.25

AM Efficacy (%)

100

98.45

97.73

94.54

98.88

G. mean (GM)^{a}

0

0.25

0.32

1.03

0.19

GM Efficacy (%)

100

98.95

98.54

95.48

99.15

Test statistic vs placebo

t
_{(19)} = 54.50

t
_{(25)} = 20.30

t
_{(19)} = 13.13

t
_{(23)} = 12.78

t
_{(26)} = 21.67

Pvalue vs placebo

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

Afoxolaner

Range

0–0

0–1

0–4

0–2

0–1

Arithmetic mean (AM)

0

0.13

1.50

0.38

0.25

AM Efficacy (%)

100

99.48

93.18

98.36

98.88

G. mean (GM)^{a}

0

0.09

1.28

0.25

0.19

GM Efficacy (%)

100

99.62

94.12

98.90

99.15

Test statistic vs placebo

t
_{(19)} = 54.50

t
_{(25)} = 21.23

t
_{(19)} = 10.60

t
_{(23)} = 15.29

t
_{(26)} = 21.67

Pvalue vs placebo

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

Test statistic vs sarolaner

t
_{(19)} = 0.00

t
_{(25)} = 0.93

t
_{(19)} = 2.53

t
_{(23)} = 2.51

t
_{(26)} = 0.00

Pvalue vs sarolaner

1.0000

0.3606

0.0204

0.0195

1.0000


^{a}
Pvalues are based on comparison of geometric means